Society for Immunotherapy of Cancer to Host Back-to-Back Workshops on Tumor Cell Surfaceome and Bispecific T cell Engagers
Share Article
The Society for Immunotherapy of Cancer (SITC) will host two timely, back-to-back workshops Sept. 29–Oct. 1, 2021, in San Diego which will address critical challenges, facilitate innovative collaborations, and develop strategies to ensure continued momentum in drug development in the field of cancer immunotherapy.
Society for Immunotherapy of Cancer
“SITC is continually developing educational and networking opportunities to create a lasting impact on clinical practice by highlighting emerging topics relevant to immuno-oncology,” said SITC President Patrick Hwu, MD. MILWAUKEE (PRWEB) April 07, 2021 The Society for Immunotherapy of Cancer (SITC) will host two timely, back-to-back workshops Sept. 29–Oct. 1, 2021, in San Diego which will address critical challenges, faci
Not for trading, but in connection with the registration of American Depositary Shares, pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
None Indicate the number of outstanding shares of each of the issuer s classes of capital or common stock as of the close of the period covered by the annual report: Title of each class
Ordinary Shares, nominal value £0.0025 per
Share 131,467,935 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]
SITC Announces Two Spatial Technology Awards for Early Career Scientists to Advance Cancer Immunotherapy Research
Share Article
The Society for Immunotherapy of Cancer (SITC) is committed to championing the next generation of cancer immunotherapy experts through dedicated support of novel research. SITC is pleased to offer domestic and international early career investigators in academia and government two unique awards that leverage spatial phenotyping and profiling technologies.
Society for Immunotherapy of Cancer
“SITC views these two unique technology awards as an investment in the future of our field that we hope will lead to innovative and cutting-edge immunotherapy approaches and ultimately better outcomes for patients,” said SITC President Patrick Hwu, MD.
Our six dermatology products are marketed by our partner company, Journey Medical Corporation (“Journey”).
Our products generated net revenues of $44.5 million for full-year 2020, compared to full-year 2019 net revenues of $34.9 million, representing growth of 28%. Our products generated $13.7 million in revenues in the fourth quarter of 2020, compared to $11.1 million in the fourth quarter of 2019, representing growth of 23%. While we generated revenue growth year-over-year in 2020, sales of our products were impacted by the COVID-19 pandemic, which caused a temporary supply shortage and impacted the ability of our sales force to make in person calls, due to states slowly re-opening.
We in-licensed and recently launched our sixth prescription dermatology product.
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.